One-sentence summary: Nitric oxide ubiquitously signals via cyclic GMP, but its feedback regulation is cGMP-independent following a non-canonical redox mechanism that is aggravated under disease conditions.
Introduction
The NO-cGMP signaling pathway plays an important role in cardiopulmonary homeostasis (1, 2).
The main receptor and mediator of NO's actions is soluble guanylate cyclase (sGC), a heterodimeric heme protein. In its Fe(II)heme-containing state, sGC binds NO and is thereby activated to convert guanosine triphosphate (GTP) to the second messenger, cGMP (3), which exerts its cardiopulmonary effects via activating cGMP-dependent protein kinase-I (PKG) (4) . This results in potent vasodilatory, anti-proliferative and anti-thrombotic effects (5) . In disease, heme loss and appearance of an apo-sGC has been described (6, 7) .
In addition to acute activation, NO appears to have further roles in sGC regulation. During enzyme maturation, NO facilitates heme incorporation into sGC (8, 9) , and activation of sGC by NO is followed by an acute and rapidly reversible desensitization involving possibly protein Snitrosylation (10) . In addition, chronic exposure to NO donor drugs has been suggested to negatively affect sGC long-term and in a not fully reversible manner (11) (12) (13) . It is unclear, however, whether this effect pertains also to endogenously formed NO and has pathophysiological relevance.
Here, we examine this important knowledge gap in the (patho)biology of NO. As model systems we chose porcine pulmonary artery endothelial cells (PPAECs) as they relate to the clinical application of NO and cGMP modulating drugs in pulmonary hypertension (14, 15) . We investigate the effects of chronic exposure to both exogenous NO donor drugs and endogenous NO on sGC protein and activity. In addition, we investigate whether such chronic mechanisms involve canonical cGMP signaling, possible thiol modulation, or formation of heme-free, apo-sGC in health and disease. For the latter, we use again an experimental model related to pulmonary hypertension and chronically elevated levels of NO, porcine acute respiratory disease syndrome (ARDS) (16) (17) (18) .
Results

NO chronically decreases vascular sGC protein and activity in vivo and in vitro.
To analyse the chronic effects of NO at a mechanistic level, we studied PPAECs. When cells were incubated for up to 72h in the presence of the NO synthase (NOS) inhibitor N G -nitro L-arginine methyl ester (L-NAME) to examine the effects of endogenously formed NO, protein levels of the heme-binding sGCβ 1 subunit were increased (Fig. 1A) . This up-regulation was associated also with increased sGC activity (Fig. 1B) . Next we wanted to test whether a further increase of NO to supraphysiological levels by chronic exposure to the long-acting NO donor compound, DETA/NO, aggravated this effect. Indeed, pre-incubating cells with DETA/NO (100 µM) decreased both sGCα 1 and sGCβ 1 protein (Fig. 1C ) and sGC activity (Fig. 1D) . Thus, in-vitro in PPAECs endogenous NO tonically downregulate sGC protein and activity, which is further aggravated by exogenous, pharmacologically applied NO in supra-physiological concentrations (Fig. 1E ).
Next, we wanted to validate these in-vitro observations at an in-vivo level in eNOS knock-out mice (eNOS -/-) and in a porcine lung disease model (ARDS) characterized by NO overproduction (16, 18, 19) . In line with our observations in PPAECs, eNOS -/-mice showed increased protein levels of sGCα 1 and sGCβ 1 (Fig. 1F ) and increased sGC-activity (Fig. 1H ). In the high-NO pulmonary disease model, sGCα 1 and sGCβ 1 protein levels ( Fig. 1G ) and sGC activity were decreased (Fig. 1I) . Collectively, these data suggest that both in-vitro and in-vivo lowering endogenous NO increases, and increasing endogenous NO lowers sGC protein subunit and sGC activity (Fig. 1E ).
PKG does not mediate the down-regulation of sGC protein and activity by chronic NO.
Next, we aimed to clarify the mechanisms underyling the downregulation of sGC protein and activity by chronic/tonic NO. First, we wanted to test whether this was due to canonical cGMP signaling via PKG. Of experimental importance, cell passaging can cause downregulation of PKG and just preclude the detection of PKG-dependent signaling (20-23). Hence, we therefore restricted our studies to low passage number cells and ensured fully functional PKG signaling by validating the known autoregulation of PKG expression (24, 25). Indeed, in our PPAEC system, both the PKG activator, 8-Br-cGMP, and the NO-independent sGC stimulator, YC-1, were able to reduce PKG expression ( Fig. S1 ) confirming the presence of fully functional PKG. We then studied whether the observed downregulation of sGC protein and activity by NO can be mimicked by cGMP or is prevented by inhibiting PKG. When we exposed PPAECs, however, for 72h with different concentrations of the sGC stimulator, YC-1, to raise cGMP in an NO-independent manner, or to the direct PKG activator, 8-Br-cGMP, neither sGC protein nor activity were lowered (cf. to Fig. 1 ). In fact, we observed even a slight up-regulation of sGC protein (Fig. 2, A and B) . Consistent with this, the NO induced down-regulation of sGC could not be prevented by co-incubation with the PKG inhibitor, Rp-8-Br-PET-cGMPS (Fig. S2) . To extend these in-vitro findings also to the in-vivo level,
we subsequently studied sGC expression and activity in PKG knock-out mice (PKG -/-) (26).
Consistent with our in-vitro data, sGC protein levels ( Fig. 2D ) and sGC activity ( Fig. 2E ) were unchanged in PKG -/-as compared to wildtype mice. In conclusion, both our in-vivo and in-vitro data suggested that the down-regulation of sGC protein and activity by chronic NO is cGMP-and PKG-independent and thus appeared to be due to a non-canonical mechanism (Fig. 2C) . Two cGMP-independent effects on sGC have been reported, rapid desensitization (10, 27, 28) , which is reversible in a thiol-dependent manner (29, 30), and oxidative heme-loss yielding the NOinsensitive apo-form of (apo-sGC) (7, 31) .
NO-induced sGC down-regulation is thiol-independent.
We first assessed the possible effect of thiols on the sGC down-regulation observed with chronic NO exposure. PPAECs were again exposed for 72 h to DETA-NO (100µM) in absence or presence, over the full time frame, of the membrane-permeable thiol-reducing agent, N-acetyl-L-cysteine (NAC; 1mM). Presence of NAC, however, did neither affect sGC protein levels (Fig. 3A) nor activity (Fig. 3B ). These data suggested that it is unlikely that a thiol-reversible mechanism similar to the acute desensitisation is involved in the chronic NO-induced downregulation of sGC protein and activity.
NO-induced sGC down-regulation generates NO-insensitive sGC.
As second possible non-canonical mechanism, we examined whether chronic NO converts sGC to NO-insensitive apo-sGC. To assay for the presence of apo-sGC, we took advantage of the apo-sGC activator drug, BAY 58-2667 (cinaciguat), which specifically binds to the empty heme binding pocket of apo-sGC, which re-activates cGMP formation (32). Indeed, up to 72 h exposure of PPAECs to DETA-NO (100 µM) increased apo-sGC activity, measured as BAY 58-2667-induced cGMP formation (Fig. 3C ), and reduced sGC activity (Fig. 1D ). To validate this mechanistic finding in-vivo, we re-examined the porcine high-NO ARDS model in which we had already observed lower sGC protein levels and activity (see Fig. 1I ). Consistent with our above in-vitro findings, apo-sGC activity was also here increased ( Fig. 3D ).
Discussion
It is unclear, however, whether this effect pertains also to endogenously formed NO and has pathophysiological relevance. Our findings provide important new understandings of NO-cGMP signaling. We expand the previously observed notion that NO donors drugs can reduce sGC mRNA levels (33) to the protein level and importantly to endogenous NO. Previously, sGC protein levels were non-consistently investigated or with antibodies of unclear specificity (11, 34) . Moreover, the functional consequences of PKG on cGMP levels were investigated only in some cases (33, 35) or in relation to cGMP metabolism rather than its formation (33, 36, 37).
Surprisingly, not only pathological high levels of NO, as in our porcine ARDS model, but already low tonic NOS activity suppressed sGC protein and activity. These findings establish a previously not recognized delicate steady state in the interactions between NO and sGC, acutely stimulating and chronically limiting its enzyme activity. On a positive note, under conditions of diminished NO synthesis, this may in turn swiftly de-inhibit and upregulate sGC protein and activity as we have observed in the presence of the NOS inhibitor, L-NAME.
Of therapeutic importance is also the previously not recognized risk of chronic use of NO donor drugs as they will downregulate both sGC protein and activity. Together with the problematic pharmacokinetics and related tolerance, this adds to the limitations of this widely used drug class.
With the introduction of NO-independent sGC stimulators into clinical practice (38) there is now an 8
alternative. Indeed, we show that the prototypic sGC stimulator, YC-1, does not lead to sGC downregulation.
With respect to the underlying mechanisms, we initially considered two known mechanisms in NO-cGMP physiology, i.e. PKG and thiol modification (9, 10). Surprisingly, both could be excluded, which was reminiscent of an earlier observation where long-term exposure to an exogenous NO donor also reduced sGC activity in a manner that could not be recovered with thiol treatment (13) . Instead, our findings suggest that endogenous and exogenous NO chronically induce a net shift from sGC to apo-sGC and that this is not only a pathophysiological mechanism but pertains to NO-cGMP physiology. This explains why apo-sGC activator-induced cGMP formation and functional effects are enhanced in but not exclusive to disease conditions (7) . Nevertheless, the availability of sGC activator compounds allows now to overcome such conditions in which sGC protein and activity is diminished in favour of apo-sGC and still induce cGMP formation.
Our findings thus also add to our understanding of apo-sGC as a therapeutic target. Hitherto aposGC has been mainly studied by using the heme oxidant, ODQ, or by expressing enzyme where the proximal heme ligating histidine had been deleted (39) . The mechanisms by which apo-sGC forms in pathophysiology were less clear. Now chronic exppsure to (high) levels of NO can be considered one of these conditions. Whether this involves additional interactions with for example reactive oxygen species and from which source remains to be investigated. Certainly, intermediate compounds such as peroxynitrite would be candidate molecule to potentiate NO's oxidative potential (40) . Of note, the shift from sGC to apo-sGC is not 1-to-1. Some sGC appears to be lost due to inactivation beyond recovery by apo-sGC activators, e.g. by channeling into the ubiquitinylation-proteasome pathway (41) . Nevertheless, an apparent net shift from sGC to aposGC as main source of cGMP formation is a common denominator and has recently also been observed by us in another high NO model of ischemic stroke (6).
In conclusion, our data suggest that both in vitro and in vivo, and both under physiological conditions and in disease NO self-limits its ability to induce cGMP formation via a chemical redox 9 feedback which causes inactivation of sGC and an apparent net shift towards NO-insensitive aposGC. Our findings are of direct therapeutic importance as a pathological sGC/apo-sGC ratio can be treated with sGC activator compounds such as BAY58-2667 (41) thereby reinstalling cGMP synthesis and PKG signaling (7, 31) . Moreover, with respect to the long-established class of NO donor drugs and the use of inhaled NO a cautionary note needs to be added. Not only do they cause tolerance, but, as we now find, also irreversible downregulation of sGC and apo-sGC formation.
This explains the superiority of the novel, NO-independent sGC stimulators, at least in indicatioins such as pulmonary hypertension (14) .
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Materials and Methods
Chemicals
Polyclonal antibodies specific for sGCα 1 and sGCβ 1 have been described elsewhere (30). Actin monoclonal antibody (Oncogene Research Products, Boston, USA); collagenase type CLS II (Merck, Netherlands); 8-bromo-cGMP (BIOLOG, Germany); L-NAME, DETA/NO, DEA/NO , IBMX and GTP (Enzo Life Sciences, Netherlands); BAY 58-2667 was synthesized as described (42) . All other chemicals were of the highest purity grade available and obtained from Sigma or Merck (Netherlands). DETA/NO and DEA/NO were dissolved in 10 mM NaOH, BAY 58-2667 and YC-1 in DMSO.
Tissue isolation
Tissues from i) 6-to 8-months old male cGK-I -/-and age-matched control mice were obtained from 
Preparation of pulmonary arteries from a porcine ARDS model
Pulmonary arteries were removed immediately after death from an experimental porcine model of ARDS, as previously described (29). Pulmonary arteries were snap-frozen in liquid nitrogen and stored at minus 80°C or otherwise processed immediately to tissue powder and subsequently suspended in homogenization-buffer and homogenized in an Ultra Turrax at 4°C. These samples were then used further for protein determination, protein immune blots and sGC activity assays.
PPAECs
Fresh porcine pulmonary arteries were obtained from a local slaughterhouse and maintained in phosphate-buffered saline (PBS; 10mM Na 2 HPO 4 , 1.8mM KH 2 PO 4 , 140mM NaCl, 2.7mM KCl, 1 1 pH 7.4) at 37°C. PPAECs were isolated enzymatically by incubation of the aorta inner surface with collagenase type CLS II (0.5 mg/mL for 10 min at room temperature) and then collected in HEPESbuffered medium 199. After centrifugation (250 x g, 10 min) the pellet was re-suspended in growth medium (medium 199 supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin) and cells were propagated in coated plastic flasks and incubated (37°C, 6% CO 2 ).
Upon confluence, endothelial cell monolayers were sub-cultured in 35-mm (for Western blot) or 60-mm (for cGMP determination) gelatin coated dishes. Confluent cell monolayers from the second passage were used for experiments. The growth medium was replaced either every 12 or 24 hours if applicable containing the indicated compounds. After incubation time cells were subsequently used for sGC activity measurements or western blot analysis.
Detection and quantification of sGC protein
Western blotting procedures were described previously (43) . Briefly, cells were lysed in 250 µL 
Determination of sGC activity
To measure sGC activity, cells were stimulated with 250 µM DEA/NO or 10 µM BAY 58-2667 for 3 min at 37°C. Thereafter, cells were immediately lysed in 80 % ethanol. Cells were scraped and, after evaporation of ethanol, re-suspended in assay buffer and sonicated. Measurement of sGC activity in crude homogenates of porcine tissue was performed as previously described (43) .
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Briefly, all samples were measured as the formation of cGMP at 37 °C during 10 min in a total incubation volume of 100 ml containing 50 mM triethanolamine-HCl (pH 7.4), 3 mM MgCl, 3 mM glutathione, 1mM IBMX, 100mM zaprinast, 5 mM creatine phosphate, 0.25 mg/ml creatine kinase and 1mM or 0.5 mM GTP. The reaction was started by simultaneous addition of the sample and either DEA/NO or BAY 58-2667, respectively. After incubation of each sample for 10 min the reaction was stopped by boiling for 10 min at 95°C. Thereafter the amount of cGMP was subsequently determined by a commercial enzyme immunoassay kit (Enzo Life Sciences, Netherlands).
Statistics
For comparisons students´ t-test or multiple comparisons one-way analysis of variance (ANOVA)
was followed by Bonferroni's test. Calculations were performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, USA). All data are expressed as mean ± SEM. 
